A Deep Dive into the "I"s of Non-cystic fibrosis bronchiectasis

Thank you

This live web event has ended. Thank you for attending.

Description

Non-cystic fibrosis bronchiectasis (NCFB) results from an initial airway Injury that leads to a cycle of Inflammation, airway remodeling, Increased mucus production, and repeated Infection (Maselli 2017 p2). Repeated infections, particularly with Pseudomonas aeruginosa, have a significant impact on quality of life, number of hospitalizations, and mortality in NCFB patients. Current approaches to treatment are associated with suboptimal disease management, adverse events, and bacterial resistance. This webinar will discuss how the severity of NCFB is characterized, current challenges in diagnosis and management, and emerging treatment strategies for severe NCFB.

This program is sponsored by Zambon

By registering for this webinar, you agree your information will be shared with the sponsor.

No CME or MOC credits are available for this program.

Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.

Contributors

James Chalmers, MBChB, PhD

Professor and Consultant Respiratory Physician
University of Dundee School of Medicine
Scotland, United Kingdom

Prof James Chalmers is a Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee. His laboratory works primarily on the interaction between neutrophils and bacteria during acute and chronic airway infections. Major areas of research with relevance to AMR include phase 1 and phase 2 studies of non-antibiotic alternative therapies for respiratory infections, the development of diagnostics to reduce antibiotic use by more accurately identifying bacterial infections and work to understand the selective drivers of antimicrobial resistance in chronic airways diseases such as bronchiectasis and cystic fibrosis where multidrug resistant Gram-negative infections are common. His work is funded by the Wellcome Trust, Medical Research Council, Scottish Government, EU and the pharmaceutical industry.
Francesco Blasi, MD, PhD, FERS

Professor of Respiratory Medicine
Department of Pathophysiology and Transplantation
University of Milan
Milan, Italy

Prof Francesco Blasi is Professor of Respiratory Medicine Department of Pathophysiology and Transplantation at the University of Milan, Italy, as well as Head of Internal Medicine Department and Respiratory Unit of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. He is also director of the Adult Cystic Fibrosis Center of the Lombardia Regional Referral CF Center and currently a member of the Board of Directors of the University of Milan. He was president of the European Respiratory Society from 2012–2013, president of the Italian Respiratory Society from 2016–2017, and since 2019, he has been vice-president of the Italian Society of Cystic Fibrosis.

Prof Blasi has published more than 450 papers in international journals [h-index (January 2022) WEB of Science: 64; SCOPUS: 58]. His research interests include pneumonia, COPD, bronchiectasis, tuberculosis and NTM infections, cystic fibrosis and lung transplantation.

Thank you

Description

Contributors

James Chalmers, MBChB, PhD

Francesco Blasi, MD, PhD, FERS